Flecainide-induced myoclonus
Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervou...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2014-03, Vol.37 (2), p.65-66 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 2 |
| container_start_page | 65 |
| container_title | Clinical neuropharmacology |
| container_volume | 37 |
| creator | Velasco, Sara Llamas Sierra-Hidalgo, Fernando Rodríguez, Rosa María Ceballos Guerreo, Antonio José Méndez Morales, Juan Ruiz |
| description | Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. Here, we report the case of a 71-year-old woman with a history of renal transplantation who developed severe myoclonus 24 hours after being started on flecainide, 100 mg 2 times a day, because of atrial fibrillation. This symptom completely disappeared once the drug was removed. Only 2 patients presenting with flecainide-induced myoclonus have been previously reported. Although the exact pathophysiologic explanation of this phenomenon remains unclear, it is well known that the susceptibility to severe flecainide toxicity is increased in patients with chronic kidney disease. |
| doi_str_mv | 10.1097/WNF.0000000000000025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1635028906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1508413452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-9a54d3f941cca2dcd97555536d0601b9bdf2a58b57f5a1f7ee41a590671086f03</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotlb_QRGXbqbem-RmJkspVgXRjaK7kMkDRuZRJ51F_70jrYJuPJu7-c658DE2R1gg6Pzq9XG1gF_hdMCmSCLPUPG3QzYFoXhGSskJO0npfUQKLfUxm3CpUCpFUzZf1cHZqq18yKrWDy74i2bbubprh3TKjqKtUzjb3xl7Wd08L--yh6fb--X1Q-aEhE2mLUkvopbonOXeeZ3TGKE8KMBSlz5yS0VJeSSLMQ9BoiUNKkcoVAQxY5e73XXffQwhbUxTJRfq2rahG5JBJQh4MTb-RwkKiUISH1G5Q13fpdSHaNZ91dh-axDMl0IzKjR_FY618_2HoWyC_yl9OxOfyiRpbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1508413452</pqid></control><display><type>article</type><title>Flecainide-induced myoclonus</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Velasco, Sara Llamas ; Sierra-Hidalgo, Fernando ; Rodríguez, Rosa María Ceballos ; Guerreo, Antonio José Méndez ; Morales, Juan Ruiz</creator><creatorcontrib>Velasco, Sara Llamas ; Sierra-Hidalgo, Fernando ; Rodríguez, Rosa María Ceballos ; Guerreo, Antonio José Méndez ; Morales, Juan Ruiz</creatorcontrib><description>Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. Here, we report the case of a 71-year-old woman with a history of renal transplantation who developed severe myoclonus 24 hours after being started on flecainide, 100 mg 2 times a day, because of atrial fibrillation. This symptom completely disappeared once the drug was removed. Only 2 patients presenting with flecainide-induced myoclonus have been previously reported. Although the exact pathophysiologic explanation of this phenomenon remains unclear, it is well known that the susceptibility to severe flecainide toxicity is increased in patients with chronic kidney disease.</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/WNF.0000000000000025</identifier><identifier>PMID: 24614665</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Anti-Arrhythmia Agents - adverse effects ; Female ; Flecainide - adverse effects ; Humans ; Myoclonus - chemically induced</subject><ispartof>Clinical neuropharmacology, 2014-03, Vol.37 (2), p.65-66</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-9a54d3f941cca2dcd97555536d0601b9bdf2a58b57f5a1f7ee41a590671086f03</citedby><cites>FETCH-LOGICAL-c340t-9a54d3f941cca2dcd97555536d0601b9bdf2a58b57f5a1f7ee41a590671086f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24614665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Velasco, Sara Llamas</creatorcontrib><creatorcontrib>Sierra-Hidalgo, Fernando</creatorcontrib><creatorcontrib>Rodríguez, Rosa María Ceballos</creatorcontrib><creatorcontrib>Guerreo, Antonio José Méndez</creatorcontrib><creatorcontrib>Morales, Juan Ruiz</creatorcontrib><title>Flecainide-induced myoclonus</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. Here, we report the case of a 71-year-old woman with a history of renal transplantation who developed severe myoclonus 24 hours after being started on flecainide, 100 mg 2 times a day, because of atrial fibrillation. This symptom completely disappeared once the drug was removed. Only 2 patients presenting with flecainide-induced myoclonus have been previously reported. Although the exact pathophysiologic explanation of this phenomenon remains unclear, it is well known that the susceptibility to severe flecainide toxicity is increased in patients with chronic kidney disease.</description><subject>Aged</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Female</subject><subject>Flecainide - adverse effects</subject><subject>Humans</subject><subject>Myoclonus - chemically induced</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUhYMotlb_QRGXbqbem-RmJkspVgXRjaK7kMkDRuZRJ51F_70jrYJuPJu7-c658DE2R1gg6Pzq9XG1gF_hdMCmSCLPUPG3QzYFoXhGSskJO0npfUQKLfUxm3CpUCpFUzZf1cHZqq18yKrWDy74i2bbubprh3TKjqKtUzjb3xl7Wd08L--yh6fb--X1Q-aEhE2mLUkvopbonOXeeZ3TGKE8KMBSlz5yS0VJeSSLMQ9BoiUNKkcoVAQxY5e73XXffQwhbUxTJRfq2rahG5JBJQh4MTb-RwkKiUISH1G5Q13fpdSHaNZ91dh-axDMl0IzKjR_FY618_2HoWyC_yl9OxOfyiRpbg</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Velasco, Sara Llamas</creator><creator>Sierra-Hidalgo, Fernando</creator><creator>Rodríguez, Rosa María Ceballos</creator><creator>Guerreo, Antonio José Méndez</creator><creator>Morales, Juan Ruiz</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20140301</creationdate><title>Flecainide-induced myoclonus</title><author>Velasco, Sara Llamas ; Sierra-Hidalgo, Fernando ; Rodríguez, Rosa María Ceballos ; Guerreo, Antonio José Méndez ; Morales, Juan Ruiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-9a54d3f941cca2dcd97555536d0601b9bdf2a58b57f5a1f7ee41a590671086f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Female</topic><topic>Flecainide - adverse effects</topic><topic>Humans</topic><topic>Myoclonus - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Velasco, Sara Llamas</creatorcontrib><creatorcontrib>Sierra-Hidalgo, Fernando</creatorcontrib><creatorcontrib>Rodríguez, Rosa María Ceballos</creatorcontrib><creatorcontrib>Guerreo, Antonio José Méndez</creatorcontrib><creatorcontrib>Morales, Juan Ruiz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Velasco, Sara Llamas</au><au>Sierra-Hidalgo, Fernando</au><au>Rodríguez, Rosa María Ceballos</au><au>Guerreo, Antonio José Méndez</au><au>Morales, Juan Ruiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Flecainide-induced myoclonus</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>37</volume><issue>2</issue><spage>65</spage><epage>66</epage><pages>65-66</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><abstract>Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. Here, we report the case of a 71-year-old woman with a history of renal transplantation who developed severe myoclonus 24 hours after being started on flecainide, 100 mg 2 times a day, because of atrial fibrillation. This symptom completely disappeared once the drug was removed. Only 2 patients presenting with flecainide-induced myoclonus have been previously reported. Although the exact pathophysiologic explanation of this phenomenon remains unclear, it is well known that the susceptibility to severe flecainide toxicity is increased in patients with chronic kidney disease.</abstract><cop>United States</cop><pmid>24614665</pmid><doi>10.1097/WNF.0000000000000025</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2014-03, Vol.37 (2), p.65-66 |
| issn | 0362-5664 1537-162X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1635028906 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Anti-Arrhythmia Agents - adverse effects Female Flecainide - adverse effects Humans Myoclonus - chemically induced |
| title | Flecainide-induced myoclonus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A15%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Flecainide-induced%20myoclonus&rft.jtitle=Clinical%20neuropharmacology&rft.au=Velasco,%20Sara%20Llamas&rft.date=2014-03-01&rft.volume=37&rft.issue=2&rft.spage=65&rft.epage=66&rft.pages=65-66&rft.issn=0362-5664&rft.eissn=1537-162X&rft_id=info:doi/10.1097/WNF.0000000000000025&rft_dat=%3Cproquest_cross%3E1508413452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1508413452&rft_id=info:pmid/24614665&rfr_iscdi=true |